RAC 0.00% $1.58 race oncology ltd

This is possible (or the other way around too), but I suspect...

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 2,801 Posts.
    lightbulb Created with Sketch. 10668
    This is possible (or the other way around too), but I suspect the reason is the dose of Carfilzomib the mice can handle is just below the threshold that has a measurable effect on the MM cells. If you have a synergistic combination then you can see effects of the combination even at doses below what can be detected when each is used on their own.

    I personally find the massive difference between in the in vitro and in vivo efficacy of carfilzomib and bisantrene to be fascinating. In cell culture carfilzomib is more than 100x more effective than bisantrene, but in the mice bisantrene is vastly more effective.
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
(20min delay)
Last
$1.58
Change
0.000(0.00%)
Mkt cap ! $268.4M
Open High Low Value Volume
0.0¢ 0.0¢ 0.0¢ $0 0

Buyers (Bids)

No. Vol. Price($)
1 249 $1.59
 

Sellers (Offers)

Price($) Vol. No.
$1.58 157 1
View Market Depth
Last trade - 09.25am 11/11/2024 (20 minute delay) ?
RAC (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.